Back

Impact of kidney dysfunction on the initiation and discontinuation of SGLT2 inhibitor therapy in patients with heart failure: a nationwide study of 41,225 patients

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Understanding prognosis in heart failure Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Mrs Deewa Zahir

Hvidovre Hospital, Copenhagen (Denmark)

7 More presentations in this session

Presentation thumbnail
Palliative care in heart failure: extent and predictors of use, and association with cause-specific hospitalisation and mortality- a Swedish retrospective cohort analysis.
Professor A. Banerjee (London, GB)
Abstract Slides Video
Presentation thumbnail
Palliative care in the current management of heart failure- a matched case-control, retrospective cohort study in England.
Professor A. Banerjee (London, GB)
Abstract Slides
Presentation thumbnail
Prevalence and prognostic significance of malnutrition assessed by two scoring systems in hospitalised elderly patients with chronic heart failure
Doctor M. El-Sheikh (Hvidovre, DK)
Abstract Slides Video
Presentation thumbnail
Prognosis of tachycardia-induced heart failure compared to heart failure of other etiology
Mr T. Ovrebotten (Nordbyhagen, NO)
Abstract Slides Video
Presentation thumbnail
The prevalence and impact of comorbidities on outcomes in heart failure - a 15-Year Hungarian Nationwide Epidemiological Study (HF-EPI-HUN)
Associate Professor T. Habon (Pecs, HU)
Abstract Slides Video

Access the full session

Session thumbnail
Understanding prognosis in heart failure

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Impact of SGLT2 inhibitor on renal function and cardiovascular outcomes in heart failure: Korean heart failure III registry
thumbnail
Congress Session
Pharmacotherapy
thumbnail
Congress Session
Further Insights into SGLT2i treatment for heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources